The Sinai Center for Thrombosis Research was founded in 1998. The center's primary focus is translational research related to thrombosis in patients undergoing interventional cardiovascular procedures.
As pioneers and world leaders in the field of antithrombotic therapy, Paul A. Gurbel, M.D. and his team have amassed one of the largest bodies of data related to platelet function in patients undergoing catheter-based coronary revascularization procedures. Other investigations have studied patients with heart attacks, the leading cause of cardiac death.
Capabilities:
- Clinical trials and outcome studies
- Antithrombotic drug development (there is a dash with anti-thrombotic here but now previously?)
- Pharmacokinetic, genetic and platelet function testing
- Biomarker core lab
- Consulting and protocol development
The center is equipped with a state-of-the art laboratory housed in an area of the hospital directly adjacent to the cardiac catheterization laboratory, the largest in the region. The center has the capacity to conduct the most intricate basic investigations of platelet physiology and coagulation. The center also has an in-patient clinical research center; where serial pharmacodynamic and pharmacokinetic studies are conducted.
Original investigations conducted by the center have been presented nationally and internationally in the most prestigious venues including the American Heart Association and American College of Cardiology Scientific Sessions, the European Congress of Cardiology and the Congress of the International Society on Thrombosis and Haemostasis. The center is particularly recognized for its landmark investigations of resistance to antiplatelet drug therapy and its clinical implications. The groundbreaking work has led to patents in the area of translational research. This center's discoveries have elucidated how drugs affect coronary thrombosis and also how selected patients remain at risk despite receiving antiplatelet therapy. The center instituted the area of investigation termed, "personalized antiplatelet therapy."